| Literature DB >> 30866859 |
Erin L Van Blarigan1,2, Hilary Chan3, Katherine Van Loon4,5, Stacey A Kenfield6, June M Chan7,6, Emily Mitchell4, Li Zhang7,4,5, Alan Paciorek7,5, Galen Joseph8, Angela Laffan5, Chloe E Atreya4,5, Yoshimi Fukuoka9, Christine Miaskowski5,9, Jeffrey A Meyerhardt10, Alan P Venook4,5.
Abstract
BACKGROUND: Over 1.3 million people live with colorectal cancer in the United States. Physical activity is associated with lower risk of colorectal cancer recurrence and mortality. Interventions are needed to increase physical activity in colorectal cancer survivors.Entities:
Keywords: Accelerometer; Cancer survivor; Colorectal cancer; Digital health; Exercise; Fitbit; Intervention; Lifestyle
Mesh:
Year: 2019 PMID: 30866859 PMCID: PMC6417122 DOI: 10.1186/s12885-019-5427-5
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Consort Flow Diagram of a pilot randomized controlled trial of a physical activity intervention among individuals with colon or rectal cancer. Lost to follow-up defined as not completing the 12-week accelerometer assessment
Demographic characteristics, clinical factors, and physical activity at enrollment of 41 colorectal cancer survivors in a pilot randomized controlled trial of a physical activity intervention
| Characteristic, mean ± SD or N (%) | Total | Intervention | Control |
|---|---|---|---|
| No. of participants | 41 | 20 | 21 |
| Age, years | 54 ± 11 | 56 ± 12 | 54 ± 11 |
| Body mass index, kg/m2 | 28.4 ± 5.9 | 29.7 ± 7.2 | 27.1 ± 4.3 |
| Male | 17 (41) | 8 (40) | 9 (43) |
| Race | |||
| White | 30 (73) | 14 (70) | 16 (76) |
| African American/Black | 1 (2) | 1 (5) | 0 (0) |
| Asian | 5 (12) | 2 (10) | 3 (14) |
| American Indian/Alaskan Native, Native Hawaiian or Pacific Islander, or Other | 5 (12) | 3 (15) | 2 (10) |
| College degree | 38 (93) | 17 (85) | 21 (100) |
| Works full-time | 26 (63) | 14 (70) | 12 (57) |
| Married | 20 (49) | 9 (45) | 11 (52) |
| Cancer site | |||
| Colon | 23 (56) | 11 (55) | 12 (57) |
| Rectum | 18 (44) | 9 (45) | 9 (43) |
| Years since diagnosis | 1.5 ± 1.5 | 1.8 ± 1.9 | 1.4 ± 1.3 |
| Tumor Stage | |||
| I | 8 (20) | 4 (20) | 4 (19) |
| II | 8 (20) | 2 (10) | 6 (29) |
| III | 24 (59) | 13 (65) | 11 (52) |
| IV | 1 (2) | 1 (5) | 0 (0) |
| Moderate-to-vigorous physical activity, minutes/day | 42 ± 21 | 33 ± 18 | 51 ± 21 |
| Steps per day | 10,453 ± 4066 | 9008 ± 3639 | 11,830 ± 4052 |
Fig. 2a Number of participants who wore their Fitbit by study day. b Number of participants who responded to each of the 46 text messages that asked for a response
Fig. 3Acceptability of 12-weeks of text messages and a Fitbit Flex to individuals with colorectal cancer. 16 intervention arm participants completed the feedback survey. All values reported are N, %
Accelerometer-measured physical activity at enrollment and 12 weeks among 41 colorectal cancer survivors participating in a pilot randomized controlled trial of a Fitbit Flex and daily text messages
| Intervention ( | Control ( | ||||
|---|---|---|---|---|---|
| Type of Physical Activity | Baseline | 12 Weeks | Baseline | 12 Weeks | Mean difference in change in activity between groups (95% CI) |
| Moderate-to-vigorous, min/day | 32.9 ± 17.9 | 46.6 ± 48.4 | 50.8 ± 20.7 | 54.5 ± 24.9 | 13.1 (− 13.5, 39.7) |
| Moderate, min/day | 32.1 ± 17.6 | 43.5 ± 39.0 | 46.9 ± 18.9 | 51.7 ± 23.2 | 9.3 (−12.8, 31.3) |
| Vigorous, min/day | 0.87 ± 0.96 | 3.1 ± 10.3 | 3.9 ± 5.2 | 2.8 ± 3.3 | 3.8 (− 1.5, 9.1) |
| Steps per day | 9007 ± 3638 | 10,047 ± 4461 | 11,829 ± 4052 | 12,541 ± 5535 | 649 (− 1581, 2878) |
a12 week accelerometer data was not available from two participants in the control arm
Non-serious adverse events potentially related to physical activity reported during a 12-week Fitbit and text messaging physical activity intervention among 41 colorectal cancer survivorsa
| Intervention ( | Control ( | |
|---|---|---|
| Low back pain, N (%) | 6 (30) | 8 (38) |
| Knee pain, N (%) | 7 (35) | 5 (24) |
| Inflammation of the joints, arthritis, N (%) | 3 (15) | 5 (24) |
| Joint pain, arthralgia, N (%) | 3 (15) | 1 (5) |
| Chest pain, N (%) | 2 (10) | 1 (5) |
| Shortness of breath, N (%) | 2 (10) | 2 (10) |
| Fatigue, N (%) | 7 (35) | 9 (43) |
| Leg cramping, N (%) | 5 (25) | 1 (5) |
| Muscle pain, N (%) | 4 (20) | 4 (19) |
aParticipants in both arms were asked to report if they had experienced any of the issues listed in Table 3 at 4, 8, and 12 weeks via an online questionnaire